Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06033703
Other study ID # 2022P000152
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 2024
Est. completion date December 2024

Study information

Verified date January 2024
Source Massachusetts Eye and Ear Infirmary
Contact Leo Kim, MD, PhD
Phone 6175237900
Email Leo_Kim@meei.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.


Description:

This is an open-label, randomized study that will test the safety and pharmacokinetics of topical netarsudil at a dose frequency of once-daily in two cohorts of patients: those with primary rhegmatogenous detachments, and those with established proliferative vitreoretinopathy. The intervention will be topical application of Netarsudil from time of diagnosis of retinal detachment to 16 weeks post-operatively. Patients will be randomized to one of the following groups: - The primary rhegmatogenous detachment cohort: A total of 24 study subjects (24 eyes) will be stratified by their lens status (12 phakic versus 12 pseudophakic). All patients will receive once per day dosing of netarsudil. - The proliferative vitreoretinopathy cohort: A total of 24 study subjects (24 eyes) will be stratified by their lens status (12 phakic versus 12 pseudophakic). All patients will receive once per day dosing of netarsudil. After surgery, patients will continue on either once per day dosing of Netarsudil.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility The primary rhegmatogenous detachment cohort will have the following selection criteria: Inclusion criteria: - Patients > 18 years old - Patients presenting for primary rhegmatogenous retinal detachment repair within 7 days of symptom onset - Patients undergoing vitrectomy or vitrectomy with scleral buckle Exclusion criteria: - Patient unable to give consent - Patient unable to follow-up - Prior history of retinal detachment incisional surgery in presenting eye - Prior history of open globe injury to presenting eye - Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication - Prior history of corneal disease, or history of corneal edema - Patient already on topical netarsudil in presenting eye - Patient without natural lens or intraocular lens implant (I.e., aphakic patients) - Patients with intraocular pressure <8mm Hg in operative eye - Active or chronic or recurrent uncontrolled ocular or systemic disease - Active or history of chronic or recurrent inflammatory eye disease - Diagnosis of proliferative diabetic retinopathy - Signs of ocular infection at presentation in either eye - Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively - Inability to use/ apply topical eye drops The proliferative vitreoretinopathy cohort will have the following selection criteria: Inclusion criteria: - Patients > 18 years old - Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma - Patients undergoing vitrectomy or vitrectomy with scleral buckle Exclusion criteria: - Patient unable to give consent - Patient unable to follow-up - Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery - Patient already on topical netarsudil in presenting eye - Patients with intraocular pressure <8mm Hg in operative eye - Active or chronic or recurrent uncontrolled ocular or systemic disease - Active or history of chronic or recurrent inflammatory eye disease - Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye - Signs of ocular infection at presentation in either eye - Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively - Inability to use/ apply topical eye drops - No Light Perception vision in operative eye - Failure to achieve intraoperative reattachment - Patient with silicone oil instilled in operative eye at time of presentation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Netarsudil Ophthalmic
Topical administration of Netarsudil

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts Eye and Ear Infirmary

References & Publications (8)

Davies E, Jurkunas U, Pineda R 2nd. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy. Cornea. 2021 Jul 1;40(7):899-902. doi: 10.1097/ICO.0000000000002691. — View Citation

Fernandez MM. Reticular Epithelial Edema in Edematous Corneas Treated with Netarsudil. Ophthalmology. 2018 Nov;125(11):1709. doi: 10.1016/j.ophtha.2018.08.004. No abstract available. — View Citation

Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, Ramirez-Davis N, Kopczynski CC, Usner DW, Novack GD; ROCKET-2 Study Group. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol. 2019 Apr;200:130-137. doi: 10.1016/j.ajo.2019.01.003. Epub 2019 Jan 15. — View Citation

Lin CW, Sherman B, Moore LA, Laethem CL, Lu DW, Pattabiraman PP, Rao PV, deLong MA, Kopczynski CC. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):40-51. doi: 10.1089/jop.2017.0023. Epub 2017 Jun 13. — View Citation

LoBue SA, Moustafa GA, Vu A, Amin M, Nguyen T, Goyal H. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review. Cornea. 2021 Aug 1;40(8):1048-1054. doi: 10.1097/ICO.0000000000002621. — View Citation

Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC; ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127. doi: 10.1016/j.ajo.2017.11.019. Epub 2017 Dec 1. — View Citation

Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma. 2020 Oct;29(10):878-884. doi: 10.1097/IJG.0000000000001634. — View Citation

Wisely CE, Liu KC, Gupta D, Carlson AN, Asrani SG, Kim T. Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series. Am J Ophthalmol. 2020 Sep;217:20-26. doi: 10.1016/j.ajo.2020.04.002. Epub 2020 Apr 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The concentration of netarsudil in the vitreous to assess its pharmacokinetic properties. Netarsudil concentration in the posterior segment of the eye, using High-performance liquid chromatography (HPLC) Through study completion, an average of 1 year
Primary Serious adverse events Unexpected serious adverse events Day 1, 7, 28, 56, 84, 126, and 168 after surgery
Secondary Number of operations within 3 months Total number of operation during the first 3 months after surgery Day 84 after surgery
Secondary Final attachment status at last follow-up Status of the retina (attached versus detached) at last follow-up visit Day 168 after surgery
Secondary Visual acuity Best-corrected visual acuity measured using Snellen chart Day 1, 7, 28, 56, 84, 126, and 168 after surgery
Secondary Spectral domain optical coherence tomography (SD-OCT) of the macula Status of the macula (mac-on versus mac-off) Day 1, 7, 28, 56, 84, 126, and 168 after surgery
Secondary Adverse events Adverse events including conjunctival injection, subconjunctival hemorrhage, and corneal verticillata, eye irritation, reticular edema of the cornea, hypotony Day 1, 7, 28, 56, 84, 126, and 168 after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04403750 - Combined Laser-surgical Technology of RRD Treatment N/A
Not yet recruiting NCT04520789 - Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy N/A
Recruiting NCT04571788 - Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
Completed NCT02834559 - Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Phase 3
Recruiting NCT01845571 - Retinal Detachment - Demographic and Clinical Survey
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Recruiting NCT02871531 - Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria N/A
Completed NCT00757536 - Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment N/A
Active, not recruiting NCT00370201 - Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Phase 3
Completed NCT00345007 - Macular Function After Scleral Buckle N/A
Recruiting NCT05331664 - Dropless Pars Plana Vitrectomy Study Phase 4
Completed NCT02841306 - Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment Phase 1
Not yet recruiting NCT02185469 - Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment N/A
Not yet recruiting NCT01647373 - Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling N/A
Completed NCT01068379 - Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation Phase 3
Not yet recruiting NCT06468397 - Acute Retinal Detachment Repair With the iSeelr^TM Retinal Detachment Repair System N/A
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Recruiting NCT06056596 - Lamivudine and Plasma Markers of Inflammation in Retinal Detachment Early Phase 1
Completed NCT01343134 - Anatomical and Functional Macular Changes in Retinal Detachment N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A